MedCheck; Psilocybin, Roluperidone, Latozinemab, Lacosamide
Incannex’s investigational psilocybin product PSX-001 appeared to be effective in relieving symptoms of generalized anxiety disorder in a phase 2 clinical trial, the company announced in February. In the PsiGAD1 trial, 72 patients with generalized anxiety disorder were randomized > to receive psychotherapy with either psilocybin or placebo for seven weeks. Their symptoms were measured with the Hamilton Anxiety Rating Scale (HAM-A) at baseline and at 11 weeks. The reduction in HAM-A score from baseline in